BERKELEY, CA and VANCOUVER, BC--(Marketwired - October 19, 2015) - BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") an immuno-oncology company focused on the development of novel cancer treatments, today announced that the Company will present at the 14th Annual BIO Investor Forum in San Francisco, California on Tuesday October 20th, 2015 at 9:30AM Pacific Time (12:30PM Eastern Time). Joseph Wagner, Ph.D., BriaCell's President and Chief Executive Officer, will provide an update on the manufacturing and clinical development of BriaCell's lead immuno-oncology product, BriaVax™.

After many months of operational developments, BriaCell is scheduled to attend numerous meetings with large pharmaceutical companies, venture capital firms, and institutions.

Details of the BriaCell presentation are as follows:

Event: 2015 BIO Investor Forum
Date: Tuesday, October 20, 2015
Time: 9:30-9:55 AM Pacific Time (12:30-12:55 PM Eastern Time)
Location: The Parc 55 Hotel, 55 Cyril Magnin St, San Francisco, CA 94102


Webcast replay available: 1 hour after conclusion of live event. A replay of the webcast will be available on this site for 90 days following the live event.

BriaCell is a cancer immunotherapy biotechnology company developing a more targeted, less toxic approach to management of cancer. Immunotherapies have come to the forefront of the fight against cancer, because they harness the body's own immune system in recognizing and selectively destroying the cancer cells, sparing normal ones. Immunotherapies in addition to generally being more targeted and less toxic, have been shown to be more likely to prevent recurrence and are not expected to produce the serious side effects seen with chemotherapy.

BriaVax™, Company's lead product is a genetically engineered whole-cell vaccine derived from a human breast tumor cell line. This highly-targeted vaccine is believed to generate strong antibody and T-cell responses, which in turn may boost the immune system to recognize and eliminate cancerous cells.

The Company has demonstrated unique and unprecedented results, and is intent on building upon these results to further advance BriaVax™ through the FDA Clinical Trials in order to help cancer patients with no other options. The results of two FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced solid tumors (17 breast cancer, 1 ovarian cancer). Most uniquely, BriaCell has achieved these results in patients who had prior failed the available therapies including various kinds of chemotherapy. In some cases, the lifespan was three to five times longer than expected. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks.

Based on the impressive results of earlier clinical trials, BriaCell is preparing to further evaluate the safety and activity of BriaVax™ in an additional Phase I/II study in 24 metastatic breast cancer patients who failed at least one prior treatment. The FDA-approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Although the focus of the Company is currently breast cancer, it recognizes that upon further proof of concept, its technology may be applicable to such other cancers as well. For further information, please refer to Company's website at or its youtube channel

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

View Full Site

Embedded Video Available:

Attachment Available:

Contact Information:

For further information contact:

BriaCell Therapeutics Corp.
820 Heinz Avenue
Berkeley, CA 94710

Joseph Wagner, Ph.D.
President and CEO
Phone: 1-888-485-6340